Posted on 13/07/2009 in Pharmaceutical Company Product News Bayer Schering Pharma has presented data relating to a global study with the positron emission tomography (PET) tracer florbetaben (BAY 94-9172).
The company made the presentation about the study, which showed that patients that had been diagnosed with the condition could be differentiated from healthy volunteers based on florbetaben uptake in their brains, at the International Conference on Alzheimer's Disease.
Dr Kemal Malik, member of the board of management and head of global development at Bayer Schering Pharma, said that the results indicate the potential of florbetaben as an "important visual adjunct" to existing dementia diagnosis tools.
"There is a high medical need for an easy, non-invasive imaging technique that supports an early and precise diagnosis of dementia and especially of Alzheimer's disease, allowing for optimised care and treatment options," he added.
Further studies on florbetaben are due to take place in the future.
In recent days, Bayer announced a deal with Celera Corporation, which will see the company gain access to five cancer-related targets for in-vivo diagnostic imaging and therapeutic development.Other news stories from 13/07/2009
Read more in the Zenopa News Archive
How this news is generated
|
